Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01350128 · ClinicalTrials.gov registry record · Phase 2
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT01350128 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 103 participants.
The verdict
NCT01350128, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
Interventions
- DRUG PT001 MDI
- DRUG Ipratropium Bromide HFA Inhalation Aerosol
- OTHER Placebo MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2011-05-01 |
| Est. Completion | 2011-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01350128
The ClinicalTrials.gov registry entry for NCT01350128 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PT001 MDI is the first listed.
NCT01350128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01350128 about?
NCT01350128 is a clinical study titled "PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
What is the current status of trial NCT01350128?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2011-05-01. Estimated completion is 2011-10-01.
What interventions are being tested in trial NCT01350128?
The interventions under investigation include: PT001 MDI (DRUG), Ipratropium Bromide HFA Inhalation Aerosol (DRUG), Placebo MDI (OTHER).
Who is sponsoring clinical trial NCT01350128?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.